Paper · 39717890
Long-term effects of neoadjuvant chemotherapy in variant histology locally advanced colon cancer: a propensity score-matched analysis.
Wang Q and 4 others. Cancer Biol Ther, 2025. Cited by 4 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Long-term effects of neoadjuvant chemotherapy in variant histology locally advanced colon cancer: a propensity score-matched analysis. Papers, record 39717890. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39717890
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Long-term effects of neoadjuvant chemotherapy in variant histology locally advanced colon cancer: a propensity score-matched analysis.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoadjuvant Therapy | Major topic |
| Colonic Neoplasms | Major topic |
| Propensity Score | Major topic |
| Humans | |
| Female | |
| Male | |
| Middle Aged | |
| Retrospective Studies | |
| Aged | |
| Chemotherapy, Adjuvant | |
| Adult | |
| Neoplasm Staging | |
| Kaplan-Meier Estimate | |
| Treatment Outcome |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9,515,529 | Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. | Am J Surg | 1998 | https://conductscience.org/library/papers/9515529 | PubMed |
| 2 | 8,953,601 | NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. | Oncology (Williston Park) | 1996 | https://conductscience.org/library/papers/8953601 | PubMed |
| 3 | 15,289,862 | Two subtypes of mucinous colorectal carcinoma characterized by laser scanning cytometry and comparative genomic hybridization. | Int J Oncol | 2004 | https://conductscience.org/library/papers/15289862 | PubMed |
| 4 | 27,664,261 | Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2016 | https://conductscience.org/library/papers/27664261 | PubMed |
| 5 | 31,661,689 | Neoadjuvant Chemotherapy for Locally Advanced T4 Colon Cancer: A Nationwide Propensity-Score Matched Cohort Analysis. | Dig Surg | 2020 | https://conductscience.org/library/papers/31661689 | PubMed |
| 6 | 25,430,983 | Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. | Acta Oncol | 2015 | https://conductscience.org/library/papers/25430983 | PubMed |
| 7 | 19,451,431 | Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19451431 | PubMed |
| 8 | 23,017,669 | Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. | Lancet Oncol | 2012 | https://conductscience.org/library/papers/23017669 | PubMed |
| 9 | 33,963,914 | Does preoperative neoadjuvant chemotherapy impact short-term surgical outcomes in patients with locally advanced colon cancer? | Int J Colorectal Dis | 2021 | https://conductscience.org/library/papers/33963914 | PubMed |
| 10 | 35,904,113 | The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency. | Cancer Med | 2023 | https://conductscience.org/library/papers/35904113 | PubMed |
1 to 10 of 40
See all 40 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,985,419 | Successful Resection of Transverse Colon Cancer Invading a Reconstructed Jejunum After Pancreaticoduodenectomy: A Case Report. | Clin Case Rep | 2026 | https://conductscience.org/library/papers/42985419 | PubMed |
| 42,593,928 | From 2D to 3D Colorectal Cancer Patient-Derived Organoids (PDOs) and In Vivo Models: Copper(II) Complexes as Promising New Antitumor Agents. | J Med Chem | 2026 | https://conductscience.org/library/papers/42593928 | PubMed |
| 42,067,703 | An interpretable survival benefit analytics framework for optimizing cancer treatment decision-making. | Med Biol Eng Comput | 2026 | https://conductscience.org/library/papers/42067703 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39717890
GET https://conductscience.org/api/papers/v1/39717890/references?page=2